Minimed Group, Inc. (B8S)
XFRA 
NASDAQ (NMS) Primary XFRA Summary
B8S Chart
MiniMed Group: Recurring Revenues And Fresh Product Cycle
MiniMed's pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED's Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off.
MiniMed Group Q1 Earnings Call Highlights
MiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.
MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating
MiniMed Group, a Medtronic spin-off, is rated a buy with an FY 2027 price target of $19, implying 15% upside. MMED's double-digit revenue growth is driven by strong international adoption, expanding CGM attach rates, and timely product launches ahead of schedule. Despite gross margin compression and widened net losses in FY 2026, robust liquidity from IPO proceeds supports ongoing product rollouts and operational improvements.
Minimed Group, Inc. (B8S) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Minimed Group, Inc. ever had a stock split?
Minimed Group, Inc. Profile
| Diversified Consumer Services Industry | Consumer Discretionary Sector | Que Thanh Dallara CEO | XFRA Exchange | US60365F1093 ISIN |
| US Country | 8,000 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
MiniMed Group, Inc. specializes in the development, manufacturing, and marketing of innovative medical devices designed specifically for diabetes management. Established in 1983 by Alfred E. Mann, the company is headquartered in Northridge, California. MiniMed Group focuses on creating solutions that empower individuals with diabetes and their healthcare providers to effectively monitor and regulate blood glucose levels, significantly improving patient outcomes and quality of life.
Products and Services
- Insulin Pumps: MiniMed's insulin pumps are designed to deliver precise doses of insulin to manage blood sugar levels continuously. These pumps offer features such as programmable dosages, bolus calculators, and customizable alerts, enabling users to maintain optimal glucose control throughout the day.
- Continuous Glucose Monitoring Systems: The continuous glucose monitoring (CGM) systems provided by MiniMed allow users to track their glucose levels in real-time. These devices use sensors placed under the skin to provide continuous readings and alerts for high or low blood sugar levels, enhancing the ability to manage diabetes proactively.
- Infusion Sets: The infusion sets are essential components of the insulin delivery systems, designed to ensure the effective and comfortable administration of insulin. MiniMed's infusion sets come in various styles and sizes to accommodate individual patient needs, making it easier for users to maintain their therapy.
- Software Platforms: MiniMed offers software platforms that integrate data from insulin pumps and CGM systems to provide comprehensive insights into a patient's glucose patterns. This information assists healthcare providers and patients in making informed decisions to optimize diabetes management strategies.
- Related Accessories: Alongside its core products, MiniMed also supplies a range of accessories that support the functionality of its medical devices. This includes carrying cases, charging stations, and additional supplies necessary for the effective use of insulin pumps and monitoring systems.
